Two years after the World Health Organization declared the Zika virus outbreak a Public Health Emergency of International Concern, researchers have made good progress in developing vaccines against the disease, with some candidates now in Phase II trials. However, the brief nature of the outbreak is making wide-scale testing of the new vaccines difficult and some research programmes have already been curtailed. Read more in The Pharmaceutical Journal.